Immix Biopharma (NASDAQ:IMMX) Rating Reiterated by HC Wainwright

Immix Biopharma (NASDAQ:IMMX)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $7.00 target price on the stock. HC Wainwright’s price objective would suggest a potential upside of 243.14% from the stock’s previous close.

Immix Biopharma Stock Down 7.3 %

Shares of Immix Biopharma stock opened at $2.04 on Tuesday. The business has a 50-day moving average price of $2.17 and a 200 day moving average price of $3.19. Immix Biopharma has a fifty-two week low of $1.55 and a fifty-two week high of $7.75. The firm has a market cap of $53.88 million, a P/E ratio of -2.19 and a beta of 0.17.

Immix Biopharma (NASDAQ:IMMX) last issued its earnings results on Thursday, May 9th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.01. As a group, equities research analysts anticipate that Immix Biopharma will post -0.88 earnings per share for the current year.

Institutional Trading of Immix Biopharma

Several institutional investors have recently modified their holdings of IMMX. OLD National Bancorp IN bought a new stake in shares of Immix Biopharma during the 4th quarter worth $69,000. Tritonpoint Wealth LLC acquired a new stake in shares of Immix Biopharma during the first quarter valued at approximately $75,000. Tocqueville Asset Management L.P. lifted its position in shares of Immix Biopharma by 89.0% in the 1st quarter. Tocqueville Asset Management L.P. now owns 37,800 shares of the company’s stock valued at $116,000 after acquiring an additional 17,800 shares in the last quarter. Jump Financial LLC acquired a new position in Immix Biopharma during the fourth quarter valued at $128,000. Finally, Imprint Wealth LLC lifted its position in shares of Immix Biopharma by 49.4% in the fourth quarter. Imprint Wealth LLC now owns 34,483 shares of the company’s stock worth $239,000 after purchasing an additional 11,400 shares in the last quarter. Institutional investors and hedge funds own 11.26% of the company’s stock.

Immix Biopharma Company Profile

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.